抗抑郁药物米氮平专利分析  

Patent analysis of the antidepressant mirtazapine

作　　者：王艳花 董丽[1] 黄哲[1] WANG Yan-hua;DONG Li;HUANG Zhe(College of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016

出　　处：《中国新药杂志》2024年第19期2005-2012,共8页Chinese Journal of New Drugs

摘　　要：米氮平是全球第一个对去甲肾上腺素和5-羟色胺具有双重抑制作用的抗抑郁药物,由欧加农股份有限公司开发。本文利用智慧芽专利检索数据库进行检索,重点从专利申请趋势、原研企业的专利布局和技术发展脉络对米氮平进行分析。本文发现原研企业在米氮平的晶型专利上布局不够严密,米氮平与其他药物联用的组合物、制剂及用途是近年的研发热点。国内制药企业可以利用米氮平技术研究空白在晶型专利上进一步研究,原研企业对米氮平的专利布局可为国内制药企业提供一定参考。Mirtazapine is the world's first antidepressant with dual inhibitory effects on norepinephrine and 5-hydroxytryptamine,and is developed by Oganon Company.In this paper,we conducted a search using the PatSnap patent search database,focusing on the analysis of mirtazapine in terms of patent application trends,patent layout of the original research companies,and the pulse of technological development.This paper found that the original research enterprise in the crystal form of mirtazapine patent layout is not tight enough,mirtazapine and other drugs in combination with the combination of compositions,preparations and uses is the hot spot of research and development in recent years.Domestic pharmaceutical companies can seize the opportunity of existed technical research gaps of mirtazapine to further research on crystal patents,and the patent layout of mirtazapine by the original research enterprise can provide certain references for domestic pharmaceutical companies.

关 键 词：米氮平 专利分析 抗抑郁药 专利布局 

分 类 号：R971.4[医药卫生—药品]